Global Fabry Disease Treatment Market Size study & Forecast, by Treatment (Enzyme Replacement Therapy, Oral Chaperone Therapy, and Other Treatments), Route of Administration (Oral Route and Intravenous Route), Distribution Channel (Hospital Pharmacies, Re

Global Fabry Disease Treatment Market Size study & Forecast, by Treatment (Enzyme Replacement Therapy, Oral Chaperone Therapy, and Other Treatments), Route of Administration (Oral Route and Intravenous Route), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Analysis, 2022-2029

Global Fabry Disease Treatment Market is valued at approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.8% over the forecast period 2022-2029. Lysosomal storage disorders are a class of diseases that includes Fabry disease. It is an uncommon hereditary condition that can impact the kidneys, heart, skin, and other organs. The patient has increasing organ failure as a result of a deficiency in the enzyme alpha-galactosidase. The fundamental cause of Fabry disease is the abnormal buildup of globotriaosylceramide, a specific type of fatty substance. Factors contributing towards the market growth include expanding base of patients suffering from Fabry disease and the growing popularity of substrate reduction therapies and gene therapies.

The National Fabry Disease Foundation (NFDF) states that ""April"" is recognized as Fabry Disease Awareness Month each year. Additionally, Fabry Australia, Fabry International Network (FIN), and MPS Society in the UK are among the organizations that formally mark April as Fabry Disease Awareness Month. Additionally, these groups increase Fabry disease awareness during the month of April. This includes educating members of the public, clients, caregivers, and medical specialists. The market is also expanding because of an increase in Fabry disease research and development. Fabry disease research and development are continuously funded by organizations across the globe. For instance, the Smart functional GLA-nano formulation for the Fabry disease study was supported by the Horizon 2020 Framework Programme (H2020) (Smart-4-Fabry). The project was initiated in 2017, and its most recent workshop was held in February 2021. However, a lack of diagnostic resources in emerging country’s market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Fabry Disease Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is expected to dominate the overall market share owing to high usage of the brand Fabrazyme and widespread of awareness related to early diagnosis of Fabry disease. However, Asia Pacific is projected to be the fastest growing region due to rise in the healthcare expenditure and growth in the Fabry disease drug market.

Major market players included in this report are:
Amicus Therapeutics, Inc
Sanofi (Genzyme Corporation)
Protalix BioTherapeutics
JCR Pharmaceuticals Co., Ltd.
Takeda Pharmaceutical Company Limited
Freeline Therapeutics Holdings PLC
ISU ABXIS
Chiesi Farmaceutici S.p.A.
BIOSIDUS
Avrobio, Inc.

Recent Developments in the Market:
 Chiesi Farmaceutici S.p.A. announced the launch of a new business unit called Chiesi Global Rare Diseases in February 2020. Additionally, the aim of this newly established business unit is to perform cutting-edge research and develop innovative products for the treatment of uncommon and ultra-rare diseases, including lysosomal storage disorders such as Fabry disease.
 Micus Therapeutics is becoming a major participant in the field of rare diseases with the introduction of Galafold, the first oral therapy for Fabry disease. Due to the expanding popularity of substrate reduction treatments and gene therapies in the market and the probable introduction of their respective pipeline medicines, lucerastat and AVR-RD-01, Idorsia and Avrobio are also anticipated to command a significant market share.

Global Fabry Disease Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Treatment, Route of Administration, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study.

The report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:
By Treatment:
Enzyme Replacement Therapy
Oral Chaperone Therapy
Other Treatments
By Route of Administration:
Oral Route
Intravenous Route
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Amicus Therapeutics, Inc
Sanofi (Genzyme Corporation)
Protalix BioTherapeutics
JCR Pharmaceuticals Co., Ltd.
Takeda Pharmaceutical Company Limited
Freeline Therapeutics Holdings PLC
ISU ABXIS
Chiesi Farmaceutici S.p.A.
BIOSIDUS
Avrobio, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.